Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan Following Aortic Valve Intervention for Aortic Stenosis
NCT03315832Phase 3Withdrawn
- Sponsor
- CHU de Limoges
- Start
- Jan 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valsartan in aortic valve stenosis, left ventricular hypertrophy (LVH), sponsored by CHU de Limoges. Planned start Jan 2023; status: withdrawn.
02
Drugs
valsartan
03
Conditions
aortic valve stenosisleft ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on NCT03315832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315832.